Production (Stage)
Atea Pharmaceuticals, Inc.
AVIR
$2.90
$0.051.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.77% | -23.85% | -32.60% | -65.80% | -49.73% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -0.48% | 16.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.22% | 17.55% | 3.90% | -3.12% | -13.82% |
| Change in Net Operating Assets | -167.79% | -146.25% | -3.73% | 203.19% | 256.13% |
| Cash from Operations | -32.27% | -58.67% | -49.15% | -36.88% | -3.91% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 16.92% | 39.21% | 89.58% | 139.42% | 116.93% |
| Cash from Investing | 16.92% | 39.21% | 89.58% | 139.42% | 116.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.37% | 3.89% | 3.89% | -22.44% | -22.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -195.04% | 3.89% | 3.89% | -22.44% | -22.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.16% | -76.48% | -1.53% | 106.26% | 95.68% |